← All trials
NCT05515770
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2022
- Primary completion
- Oct 31, 2025
- Completion date
- Feb 28, 2026
- First posted
- Aug 25, 2022
- Last posted
- Aug 29, 2022
- Enrollment
- 1200
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oswaldo Cruz FoundationLead sponsor
- Evandro Chagas Institute of Clinical ResearchCollaborator
- Oswaldo Cruz FoundationReponsible party - principal investigator
- Oswaldo Cruz FoundationSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.